Oculis Holding AG
OCS
Company Profile
Business description
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
Contact
Bahnhofstrasse 20
Zug6300
CHET: +41 417119325
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
49
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,806.40 | 64.50 | 0.74% |
| CAC 40 | 7,791.47 | 13.40 | -0.17% |
| DAX 40 | 24,174.32 | 130.14 | -0.54% |
| Dow JONES (US) | 42,761.76 | 1.11 | -0.00% |
| FTSE 100 | 8,832.28 | 5.63 | -0.06% |
| HKSE | 24,232.49 | 51.06 | 0.21% |
| NASDAQ | 19,591.24 | 61.28 | 0.31% |
| Nikkei 225 | 38,473.97 | 385.40 | 1.01% |
| NZX 50 Index | 12,572.34 | 33.08 | 0.26% |
| S&P 500 | 6,005.88 | 5.52 | 0.09% |
| S&P/ASX 200 | 8,581.20 | 65.50 | 0.77% |
| SSE Composite Index | 3,404.24 | 4.47 | 0.13% |